Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I–IV Non–Small Cell Lung Cancer
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (2) , 228-235
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
- F. Hoffmann-La Roche
This publication has 25 references indexed in Scilit:
- Personalized Sequencing and the Future of Medicine: Discovery, Diagnosis and Defeat of DiseasePharmacogenomics, 2014
- Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASFrontiers in Oncology, 2014
- Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assaysBMC Cancer, 2014
- The causes and consequences of genetic heterogeneity in cancer evolutionNature, 2013
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- Cancer heterogeneity: implications for targeted therapeuticsBritish Journal of Cancer, 2013
- Circulating Tumor Cells: Liquid Biopsy of CancerClinical Chemistry, 2013
- Non–Small Cell Lung CancerJournal of the National Comprehensive Cancer Network, 2010
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2005